Vi­iV's long-act­ing HIV in­jectable Cabe­nu­va pre­ferred over Bik­tarvy by 90% of pa­tients in PhI­II tri­al

Most HIV pa­tients in a Phase III study in­ves­ti­gat­ing Vi­iV Health­care’s long-act­ing in­jectable Cabe­nu­va and Gilead Sci­ences’ dai­ly pill Bik­tarvy pre­ferred the in­jec­tion over the pill, cit­ing a range of phys­i­cal and emo­tion­al ben­e­fits.

Pa­tients al­so re­port­ed im­proved ad­her­ence to the med­ica­tion and emo­tion­al and psy­cho­log­i­cal ben­e­fits.

Vi­iV said Mon­day that it put Cabe­nu­va and Bik­tarvy head-to-head in the Phase III SO­LAR study, which found that the in­jectable was “non-in­fe­ri­or” to Bik­tarvy in ef­fi­ca­cy and pre­ferred by 90% of pa­tients af­ter 12 months of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER